Xconomy: New York Biotech – How to make it here
6:15 - 6:45 PM The Rgenix Story: From our beginnings as a small spin-out from Rockefeller University to a world-class team with multiple clinical programs and $40M in Series C funding, our executives tell the story of our Manhattan-based biotechnology company. Masoud Tavazoie -
Rgenix CEO Masoud Tavazoie Discusses Immune System Regulation in Cancer at Plenary Session during AACR Meeting
On November 28, 2018, Masoud Tavazoie, Co-Founder and CEO of Rgenix, made a presentation at AACR’s Tumor Immunology and Immunotherapy conference in Miami, Fl. As part of his presentation, Masoud described the LXR/ApoE pathway and its role in regulating the innate
AACR Tumor Immunology and Immunotherapy Conference
AACR Tumor Immunology and Immunotherapy Conference November 27 - 30, 2018 | Loews Miami Beach Hotel, Miami Beach, Florida, USA Wednesday, Nov. 28 - Plenary Session 3: Metabolic Regulation in Tumors: Implications for Therapy Session Chair: Matthew G. Vander Heiden, David H. Koch Institute
Rgenix Raises $40M in Series C Funding To Support Clinical Stage Oncology Programs
Lepu Holdings Limited leads the financing syndicate and is joined by existing major investors Novo Holdings A/S and Sofinnova Partners New York, NY – October 9, 2018 — Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer
Rgenix Presents Data on Phase I Clinical Activity For RGX-104 at the 2018 ASCO Annual Meeting
RGX-104 shown to be well-tolerated and capable of generating immunologic and anti-tumor activity in advanced cancer patients. Rgenix continues Phase Ia/b trial with a RGX-104 monotherapy expansion cohort and dose escalation/ expansion cohorts of RGX-104 in combination with nivolumab. New York,
Rgenix To Present Data on RGX-104 Clinical Activity at 2018 ASCO Annual Meeting
New York, NY – May 31, 2018 — Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that it will present its abstract on RGX-104’s pharmacodynamic and clinical activity at the 2018
Pharmacodynamic and clinical activity of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies
Presentation Monday, June 4, 2018, at ASCO. RGX-104 is a small-molecule LXR agonist that modulates innate immunity via transcriptional activation of the ApoE gene. To read the abstract, please click here.
Rgenix Announces Publication In Cell Demonstrating Activation of LXR/ApoE with RGX-104 Enhances Antitumor Immunity
LXR/ApoE Pathway Identified as Key Regulator of Innate Immune Suppression in Cancer FOR IMMEDIATE RELEASE New York, NY – January 11, 2018– Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today the publication of clinical
Liver X Factor
How Rgenix’s Liver X Agonist Could Help Overcome Checkpoint Resistance in Cancer. To read the full article, please click here.
Rgenix Reports Phase I Data for Cancer Compound RGX-104
Rgenix Inc. (New York, N.Y.) reported preliminary data from a Phase Ia/Ib trial showing that oral RGX-104 led to 4 cases of stable disease among 12 evaluable patients with advanced solid malignancies and lymphoma. To read the full article, please